CEO quits medical devices firm as restated results plunge it into the red
Tissue Regenix has revealed its CEO Daniel Lee has stepped down with immediate effect as the company said it has restated its 2024 results following the discovery of 'financial inaccuracies'.
The York-based regenerative medical devices firm said that a review of year-end inventory and cost of sales for the financial year ended 31 December 2024 has resulted in adjusted EBITDA being revised from a previously reported $1.9m profit to a $1.0m loss.
The restatement has also had a knock-on impact on the first half of 2025, with adju... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
